Monoclonal Antibody Therapy
The Apollo Hospital on Friday said they have started an “antibody cocktail treatment” for COVID19 patients, who have mild symptoms and comorbidities. These are people who have the risk of developing a severe illness, the hospital said. A 65yearold man from Delhi, who has multiple comorbidities, was the first COVID19 patient to receive “monoclonal antibody therapy”.
“Apollo Hospitals begins offering the antibody cocktail [Casirivimab and Imdevimab] to patients with mild and moderate COVID and at high risk of developing severe COVID,” the hospital said in a statement.
For advanced treatment, comprising neutralising monoclonal antibodies for our patients with COVID19. Monoclonal antibodies bind to and ‘neutralise’ the SARSCoV2 virus. We are confident this treatment option will significantly boost our efforts to bring the pandemic under control and help prevent the progression of the disease in those with mild to moderate COVID19”.
d the reason this therapy is termed as an antibody cocktail is because it comprises a mixture of more than two biological drugs (Casirivimab and Imdevimab) that mirror the human antibodies in the immune system.
”This consequently help fight the infection, similar to the natural antibodies produced when one gets infected with COVID. Both strengthen the immune defence system. This drug is said to restrict pathogens and virus from entering the patient’s body, from where they otherwise would have derived nutrition and multiplied,” Dr. Chawla said.
What are monoclonal antibodies?
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.